Fumarate Hydratase (fh) - Cancer Science

Relevant Publications

Functional implications of fumarate-induced cysteine succination.

Issue Release: 2024

Segregation, immunohistochemical, molecular and functional analyses classify a novel missense variant in fumarate hydratase (FH) as pathogenic.

Issue Release: 2024

[2022 WHO classification of renal cell carcinomas: Focus on papillary renal cell carcinoma].

Issue Release: 2024

The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates.

Issue Release: 2024

Fumarate hydratase-deficient renal cell carcinoma: an oncology care institutional experience.

Issue Release: 2024

Case report: response to immunotherapy and association with the fh gene in hereditary leiomyomatosis and renal cell cancer-associated renal cell cancer.

Issue Release: 2024

Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.

Issue Release: 2024

Memory/active T cell activation is associated with immunotherapeutic response in fumarate hydratase-deficient renal cell carcinoma.

Issue Release: 2024

Benign metastasizing fumarate hydratase (FH)-deficient uterine leiomyomas: clinicopathological and molecular study with first documentation of multi-organ metastases.

Issue Release: 2024

High-intensity focused ultrasound ablation in the treatment of fumarate hydratase-deficient uterine leiomyoma.

Issue Release: 2024

Ferroptosis: a promising target for fumarate hydratase-deficient tumor therapeutics literature review.

Issue Release: 2024

Immunohistochemical characteristics of uterine lipoleiomyomas.

Issue Release: 2024

Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the novel NAMPT Inhibitor OT-82.

Issue Release: 2024

Chromatin Helicase CHD6 Establishes Pro-inflammatory Enhancers and is a Synthetic Lethal Target in FH-Deficient Renal Cell Carcinoma.

Issue Release: 2024

Fumarate hydratase-deficient renal cell carcinoma: a single institution-based study of 29 patients by clinicopathological, immunohistochemical and genetic approaches.

Issue Release: 2024

Complete response to fifth-line anti-PD-1 rechallenge in fumarate hydratase-mutated papillary renal cell carcinoma.

Issue Release: 2024

[Succinate Dehydrogenase-Deficient Renal Cell Carcinoma: Clinicopathological Analysis of 11 Cases].

Issue Release: 2024

Case report: A rare low-grade fumarate hydratase-deficient renal cell carcinoma.

Issue Release: 2024

Fumarate Hydratase-Deficient Leiomyoma with Double Mutation Sites in the FH : A Rare Case Report and Literature Review.

Issue Release: 2024

Hereditary leiomyomatosis and renal cell cancer (HLRCC), pheochromocytoma (PCC)/paraganglioma (PGL) and germline fumarate hydratase (FH) variants.

Issue Release: 2024

How Does Arsenic Exposure Occur?

Can eliminating sugar from the diet help in cancer treatment?

How can healthcare providers support the psychological needs of cancer patients?

How is Mechlorethamine Administered?

What is the Impact of Uncontrolled Proliferation on Tumor Formation?

What are Oncolytic Bacteria?

What is the Future of Cancer Vaccines?

What are Transdermal Patches?

How Do Biolabs Contribute to Cancer Research?

What Are Some Challenges?

Partnered Content Networks

Relevant Topics